Mastering the Evolving Treatment Landscape in HER2-Positive Breast Cancer: Current Guidance and Future Perspectives

Provided by Clinical Care Options, LLC, in collaboration with RealCME

Acknowledgment

Supported by educational grants from Puma Biotechnology, Inc. and Seagen Inc.

Learning Objectives

Upon completion of this activity, learners should be able to:

• Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive breast cancer from early stage through multiple lines of treatment for MBC
• Discuss with patients the relative value of different adjuvant and extended adjuvant approaches with sensitivity for the patient’s preferences and risk of progression
• Plan effective therapy for patients with HER2-positive MBC with or without CNS metastases incorporating existing and emerging targeted treatments
• Describe the mechanism of action, efficacy results, and toxicity profile of the most newly approved and promising investigational HER2-targeting agents
• Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Aditya Bardia, MD, MPH, has disclosed that he has received consulting fees from Daiichi Sankyo/AstraZeneca, Eli Lilly, Foundation Medicine, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Phillips, Radius Health, and Sanofi and funds for research support from Daiichi Sankyo/AstraZeneca, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Natera, Novartis, Pfizer, Radium Health, and Sanofi. 

Claudine Isaacs, MD, has disclosed that she has received consulting fees from AmerisourceBergen, AstraZeneca, Biotheranostics, Eisai, Genentech, Immunomedics, Novartis, Pfizer, Puma, Sanofi, and Seagen.

Staff

CCO staff have no relevant conflicts of interest to report.

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN has disclosed she has received speaker fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead, Lilly, Morphosys, Pfizer, and Regeneron.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with HER2-positive breast cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatment for patients with HER2-positive breast cancer.

Accreditation Information
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this other activity, Gather-ed, for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
CCO designates this continuing education activity for 3.5 contact hour (.35 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-125-H01-P

Type of Activity: Application

Upon successfully completing the activity requirements listed below, transcript information will be sent to the NABP CPE Monitor Service within 60 days. 

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.5 contact hours.

Program Medium
This program has been made available online.

Instructions for Credit
Participation in this activity should be completed in approximately 3.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from 5/25/22 through 5/25/23:

1. Register online at https://clinicaloptions.gathered.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity.
4. To claim the maximum amount of credit available, you must complete all of the following:

• Completion of the Baseline and Final assessment Modules (70% passing score on the Final Assessment): 1.0 credit hours
• Completion of the Self Study Modules: 1 credit hour
• Participate in Live Group Discussion 1: 0.5 credit hours
• Participate in Live Group Discussion 2: 0.5 credit hours
• Completion of Group Task 1: 0.25 credit hours
• Completion of Group Task 2: 0.25 credit hours

Credit can be claimed upon the completion of the Post Group Assessment, which is issued when groups close.